Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

10-day more efficient than 14-day nonbismuth quadruple therapy for H. pylori eradication

24 Jun 2020

The 10-day concomitant nonbismuth quadruple regimen for the treatment of Helicobacter pylori infection remains the most efficient strategy as compared with the 14-day therapy, results of a Greek study have shown.

A total of 364 patients with newly diagnosed H. pylori infection were randomly assigned to receive either a 10-day or a 14-day concomitant nonbismuth quadruple therapy. The investigators assessed the treatment outcome using C13-urea breath test and/or histology at least 4 weeks after therapy. They also performed intention-to-treat and per-protocol analyses of the eradication rates. Secondary outcomes were patient adherence, safety, and the impact of prior antibiotic exposure in treatment efficacy.

The intention-to-treat analysis revealed comparable overall eradication rates for the 10- and 14-day treatments (87.9 percent vs 87.4 percent; p=1.000). In the per-protocol analysis, the corresponding rates were 93 percent and 94.1 percent (p=0.859). Compliance rates were excellent in both treatment arms (99.5 percent for the 10-day vs 96.2 percent for the 14-day strategy; p=0.067).

Few serious adverse events that led to the discontinuation of both regimens were reported, with no statistical difference between the two groups (0.5 percent in the 10-day vs 2.2 percent in the 14-day group; p>0.05). In terms of treatment efficacy, previous antibiotic exposure was not significant.

“In Greece, a region with >20-percent clarithromycin resistance where bismuth is unavailable, the 10-day quadruple concomitant scheme has already been adopted as the accepted first-line H. pylori eradication treatment,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.